Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA…
BERKELEY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of studies in primary human T cells…